StockData
NovaBridge Biosciences logo

NovaBridge Biosciences (NBP) stock

NBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 0/30
$0.82+0.03 (+3.89%)

Close on Nov 17, 2026Market cap $94.88MP/E –Yield –

NovaBridge Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

NovaBridge Biosciences's R&D Expenses for the twelve months ending Dec 31, 2020 was CN¥984.69M, up 17.2% year over year. For fiscal 2023 it was CN¥810.65M, down 10.4% from the year before. The highest annual figure on record is CN¥1.21B in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2023Dec 31, 2023CN¥810.65M-10.4%
FY2022Dec 31, 2022CN¥904.90M-25.4%
FY2021Dec 31, 2021CN¥1.21B+23.2%
FY2020Dec 31, 2020CN¥984.69M+17.2%
FY2019Dec 31, 2019CN¥840.42M+97.3%
FY2018Dec 31, 2018CN¥426.03M+59.5%
FY2017Dec 31, 2017CN¥267.08M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2020Dec 31, 2020CN¥286.23M–
Q4 FY2019Dec 31, 2019CN¥262.04M–

More NovaBridge Biosciences figures

See a number that looks wrong?